Target Audience

This activity was developed for national audience (US) dermatologists, pediatric dermatologists, allergists, along with nurse practitioners and physician assistants within those specialties who manage patients with atopic dermatitis.

Learning Objectives

At the conclusion of this activity, participants should be better able to:

• Recognize essential and important signs and symptoms that should be considered in the diagnosis of atopic dermatitis (AD)
• Develop treatment plans that address both symptoms and patient concerns
• Integrate newly-approved AD therapies into treatment plans
• Describe emerging AD treatments in late-stage clinical development

Faculty

Accreditation

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The Annenberg Center for Health Sciences is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 040207. This program is designated for up to 1.75 contact hours. Program ID# 5694-EM.

Disclosure Statement

It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.

The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:

Steven R. Feldman, MD, PhD

• Research Support: AbbVie: Clinical area: Psoriasis; Celgene: Clinical area: Psoriasis; Janssen: Clinical area: Psoriasis; Lilly: Clinical area: Psoriasis; Novartis: Clinical area: Psoriasis; Pfizer: Clinical area: Atopic Dermatitis; Taro: Clinical area: Psoriasis, Atopic Dermatitis
• Consultant: AbbVie: Clinical area: Psoriasis; Alvotech: Clinical area: Psoriasis; Boehringer: Clinical area: Psoriasis; Bristol-Myers Squibb: Clinical area: Atopic Dermatitis; Celgene: Clinical area: Psoriasis; Janssen: Clinical area: Psoriasis; Leo: Clinical area: Psoriasis; Lilly: Clinical area: Psoriasis; Merck: Clinical area: Psoriasis; Novartis: Clinical area: Psoriasis; Ortho: Clinical area: Psoriasis; Regeneron: Clinical area: Atopic Dermatitis; Samsung: Clinical area: Psoriasis; Sanofi: Clinical area: Atopic Dermatitis; Sun: Clinical area: Psoriasis
• Speakers Bureau: AbbVie: Clinical area: Psoriasis; Celgene: Clinical area: Psoriasis; Janssen: Clinical area: Psoriasis ; Leo: Clinical area: Psoriasis; Lilly: Clinical area: Psoriasis; Novartis: Clinical area: Psoriasis; Ortho: Clinical area: Psoriasis; Regeneron: Clinical area: Atopic Dermatitis; Sanofi: Clinical area: Atopic Dermatitis; Sun: Clinical area: Psoriasis
• Significant Shareholder: Causa Research; DrScore

Jonathan Silverberg, MD, PhD, MPH

• Research Support: GlaxoSmithKline: Clinical area: Atopic Dermatitis
• Consultant: AbbVvie: Clinical area: Atopic Dermatitis
  Asana: Clinical area: Atopic Dermatitis
  Dermavant: Atopic Dermatitis
  Galderma: Clinical area: Atopic Dermatitis
  GlaxoSmithKline: Clinical area: Atopic Dermatitis
  Glenmark: Clinical area: Atopic Dermatitis
  Kiniksa: Clinical area: Atopic Dermatitis
  Leo: Clinical area: Atopic Dermatitis
  Lilly: Clinical area: Atopic Dermatitis
  Menlo: Atopic Dermatitis
  Pfizer: Atopic Dermatitis
  Realm: Atopic Dermatitis
  Regeneron-Sanofi: Atopic Dermatitis
  
• Speakers Bureau: Regeneron-Sanofi: Atopic Dermatitis

The faculty for this activity has disclosed that there will be discussion about the use of products for non-FDA approved applications.

Additional Content Planners

Keyan Matinpour, MD (Peer Reviewer): No significant relationships to disclose.

Heather Jimenez, NP (Nurse Planner): No significant relationships to disclose.

Greg Scott, RPH, PharmD (Medical Writer): No significant relationships to disclose.

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient's unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

This activity is supported by an independent educational grant from Pfizer.

This activity is an online enduring material. Successful completion is achieved by reading and/or viewing the material, reflecting on its implications in your practice, and completing the assessment component.

The estimated time to complete the activity is 1.75 hours.

This activity was originally released on March 31, 2019 and is eligible for credit through March 30, 2020.

Our Policy on Privacy

Annenberg Center for Health Sciences respects your privacy. We don’t share information you give us, or have the need to share this information in the normal course of providing the services and information you may request. If there should be a need or request to share this information, we will do so only with your explicit permission. See Privacy Statement and other information at http://www.annenberg.net/privacy-policy/

Contact Information